StreetInsider.com News Articles

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Thu, 10 Sep 2026 09:30:00 -0400

Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001
in new indications and combination regimens

IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration

LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, IMUNON and the NCI’s Cancer Therapy Evaluation Program (CTEP) who

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Thu, 10 Sep 2026 09:30:00 -0400

Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001
in new indications and combination regimens

IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration

Imunon schedules R&D Day to discuss IMNN-001 ovarian cancer trials

Wed, 09 Sep 2026 08:32:46 -0400

IMUNON, Inc. (Nasdaq: IMNN) announced the agenda and speaker lineup for its R&D Day event, scheduled for September 23, 2026, at 10:00 a.m. ET at the Sofitel New York in New York City. The event will also be available via live webcast.

The event will feature presentations on IMNN-001, the company's investigational IL-12 immunotherapy for advanced ovarian cancer. Speakers will include researchers and principal investigators from the company's ongoing Phase 3 OVATION 3 clinical trial and its Phase 2 minimal residual disease (MRD) study, conducted in partnership with the Break Through Cancer Foundation.

Scheduled presentations include updates on IMNN-001 clinical data, a

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

Wed, 09 Sep 2026 08:30:00 -0400

Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET

LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the Company’s investigational IL-12 immunotherapy. The event will be held at the Sofitel New York in New York City on Wednesday, September 23, 2026, beginning at 10:00 a.m. ET.

To register to attend

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

Wed, 09 Sep 2026 08:30:00 -0400

Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET

To register to attend

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

The event will focus on the company's lead clinical program, IMNN-001, an IL-12 DNA plasmid immunotherapy being evaluated for the treatment of newly diagnosed advanced ovarian cancer. Presentations will cover the ongoing Phase 3 OVATION 3 trial and updates from the company's Phase 2 minimal residual disease trial, conducted in partnership with Break Through Cancer and led by researchers at The University of Texas MD Anderson Cancer Center.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to hold R&D Day on Sept. 23 focused on ovarian cancer trial

Wed, 26 Aug 2026 08:30:25 -0400

Imunon, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day for investors, analysts, and media on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

The event will focus on the company's lead clinical program, IMNN-001, an IL-12 DNA plasmid immunotherapy being developed for the treatment of advanced ovarian cancer. Presentations will cover progress in the ongoing pivotal Phase 3 OVATION 3 trial and upcoming milestones for the program.

Oncology experts and company management are scheduled to present. Topics will include data and science supporting IMNN-001, as well as

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

Wed, 26 Aug 2026 08:30:00 -0400

Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones

A patient treated with IMNN-001 will share firsthand perspective on her treatment journey and life following participation in the clinical trial